



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

ESPS Peer-review Report

Name of Journal: World Journal of Hematology

ESPS Manuscript NO: 7072

Title: Myelofibrosis: prognostication and cytoreductive treatment

Reviewer code: 00148365

Science editor: Yuan Qi

Date sent for review: 2013-11-04 19:50

Date reviewed: 2013-11-08 23:48

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a comprehensive and updated review on the prognosis and treatment of idiopathic myelofibrosis. All the parts of the manuscript are well balanced and provide useful information. Only minor changes are suggested 1. Page 4 (top). Given that the concept of complex karyotype can vary among diseases, I suggest including the definition of complex karyotype for myelofibrosis. 2. Page 11 and 12. Given the importance of the data of long-term follow-up of COMFORT-2 trial (2 years and 3 years), I suggest including the 95% confidence intervals corresponding to the HR of 0.58 and 0.48, respectively.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

ESPS Peer-review Report

Name of Journal: World Journal of Hematology

ESPS Manuscript NO: 7072

Title: Myelofibrosis: prognostication and cytoreductive treatment

Reviewer code: 02445162

Science editor: Yuan Qi

Date sent for review: 2013-11-04 19:50

Date reviewed: 2013-12-04 00:45

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a well-written and well-organized review article on the prognostication and cytoreductive treatment of myelofibrosis. One minor suggestion: the authors should briefly introduce the progress of application of allogeneic stem cell transplantation (ASCT) in treatment of myelofibrosis, since ASCT represents one of the major curative treatments of myelofibrosis.